Prostate cancer: estimating the benefits of PSA screening.

Prostate cancer: estimating the benefits of PSA screening.

Two groundbreaking trials have this year reported conflicting results as to the benefit of screening for prostate cancer. Careful interpretation in the light of contemporary data is needed to reveal the value of this intervention.

Bibliographic Details
Main Authors:	Vickers, A, Lilja, H
Format:	Journal article
Language:	English
Published:	2009

Similar Items

We need a better marker for prostate cancer. How about renaming PSA?
by: Vickers, A, et al.
Published: (2012)

PSA is dead, long live PSA.
by: Vickers, A, et al.
Published: (2012)

Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer.
by: Lilja, H
Published: (2001)

Screening for prostate cancer.
by: Carlsson, S, et al.
Published: (2012)

Prostate cancer screening with PSA: "Aequanimitas"
by: Marcus V. Sadi Dr.
Published: (2013-07-01)

Urological cancer: Time for another rethink on prostate cancer screening.
by: Vickers, A, et al.
Published: (2012)

Screening for prostate cancer: To the editor
by: Carlsson, S, et al.
Published: (2012)

Screening for prostate cancer: early detection or overdetection?
by: Vickers, A, et al.
Published: (2012)

Can PSA velocity predict risk of death in men with prostate cancer?
by: Lilja, H, et al.
Published: (2007)

Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level.
by: Törnblom, M, et al.
Published: (2001)

Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: report of the PSA committee.
by: Blijenberg, BG, et al.
Published: (2003)

Metastatic prostate cancer in the modern era of PSA screening
by: Philip A. Fontenot Jr, et al.

Testing new PSA subforms to enhance the accuracy of predicting cancer risk and disease outcome in prostate cancer.
by: Lilja, H
Published: (2008)

Association between polymorphisms in the prostate-specific antigen (PSA) promoter and release of PSA.
by: Sävblom, C, et al.
Published: (2009)

Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age.
by: Sävblom, C, et al.
Published: (2005)

Quantitative PSA RT-PCR for preoperative staging of prostate cancer.
by: Kurek, R, et al.
Published: (2003)

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
by: Ulmert, D, et al.
Published: (2008)

Impact of numeracy on understanding of prostate cancer risk reduction in PSA screening.
by: Kevin Koo, et al.
Published: (2017-01-01)

Prostate cancer screening with PSA: new data, old debate
by: Stefania Sciallero, et al.
Published: (2011-12-01)

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
by: Denmeade, SR, et al.
Published: (2003)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
by: Savage, C, et al.
Published: (2010)

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
by: Steuber, T, et al.
Published: (2007)

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section.
by: Khatami, A, et al.
Published: (2007)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
by: Naseruddin Höti, et al.
Published: (2023-02-01)

Association of Obesity and Smoking With PSA and PSA Velocity in Men With Prostate Cancer
by: Amit M. Algotar PhD, MBBS, et al.
Published: (2011-05-01)

Erratum: Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level (British Journal of Urology International 87 (638-642))
by: Törnblom, M, et al.
Published: (2001)

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
by: O'Brien, M, et al.
Published: (2009)

Erratum: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section (International Journal of Cancer (2007) 120, (170-174))
by: Khatami, A, et al.
Published: (2007)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
by: Lilja, H, et al.
Published: (2008)

Finding the PSA-based screening stopping age using prostate cancer risk
by: Azin Nahvijou, et al.
Published: (2024-01-01)

Dynamics of Medical Screening: A Simulation Model of PSA Screening for Early Detection of Prostate Cancer
by: Özge Karanfil
Published: (2023-05-01)

CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS
by: Daniel Simanjuntak, et al.
Published: (2016-03-01)

Relation between Serum Level of Total PSA and Free PSA/Total PSA Ratio with Grade of Prostate Cancer
by: Mohammad Yazdani, et al.
Published: (2013-10-01)

Screening for prostate cancer: an update.
by: Shariat, S, et al.
Published: (2008)

Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.
by: Wiklund, F, et al.
Published: (2009)

Predicting prostate cancer many years before diagnosis: how and why?
by: Vickers, A, et al.
Published: (2012)

Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
by: Björk, T, et al.
Published: (2001)

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
by: Steuber, T, et al.
Published: (2006)

Evaluation of a rapid one-step PSA test for primary prostate cancer screening
by: Shingo Ashida, et al.
Published: (2021-09-01)

Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial
by: Urban Emmenegger, et al.
Published: (2022-11-01)